Ardelyx, Inc. · 1 day ago
Clinical Records Specialist I
Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative medicines. They are seeking a Clinical Records Specialist I to perform quality reviews and manage trial-related records in compliance with regulatory standards and company procedures.
BiotechnologyHealth CareMedical
Responsibilities
Conduct quality reviews on trial records according to applicable GCP/ICH regulations and GDP guidelines including ALCOA and ALCOA+ principles and company SOPs and WIs
Apply proper classification and metadata to essential records per the study TMF Plan, and index
Generate, track and work alongside internal/external stake holders on quality issues/findings
Support the receipt and shipment of physical trial records to/from long term offsite storage
Complete the updates of study specific trackers, including the TMF index, when needed
Identify, communicate, and follow up on trial record deficiencies
Qualification
Required
Bachelor's degree with 1+ years of direct experience working with TMF records or equivalent research/pharmaceutical experience
Experience with the TMF Reference Model, GCP/ICH and GDP standards and applicable regulatory requirements
Excellent organizational skills, follow-through, and attention to detail
Excellent oral and written communication skills
Ability to work independently on routine assignments or under supervision on new assignments
Quality and timelines focused
Proficient in MS Office products (e.g. Excel, Power Point & Word) and eTMF system (e.g., Veeva, Medidata, Phlex)
Preferred
Smartsheet experience is a plus
Benefits
401(k) plan with generous employer match
12 weeks of paid parental leave
Up to 12 weeks of living organ and bone marrow leave
Equity incentive plans
Health plans (medical, prescription drug, dental, and vision)
Life insurance and disability
Flexible time off
Annual Winter Holiday shut down
At least 11 paid holidays
Company
Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs.
Funding
Current Stage
Public CompanyTotal Funding
$557.68MKey Investors
HealthCare Royalty PartnersSLR Capital PartnersNew Enterprise Associates
2022-06-30Post Ipo Debt· $20M
2022-02-24Post Ipo Debt· $27.5M
2019-12-12Post Ipo Equity· $125M
Recent News
2026-01-09
2026-01-09
2026-01-03
Company data provided by crunchbase